Mumbai-based pharma company in the oral healthcare segment, ICPA Health Products has introduced its newest oral healthcare solution – Coolora Spray. Specifically designed as a mouth spray, the product effectively addresses inflammatory and painful conditions in the mouth and throat, including post-tonsillectomy pain control, pharyngitis, laryngitis, oral mucositis, mouth ulcers and burning sensations. 

Coolora Spray proves highly effective in reaching the tonsils and posterior pharyngeal wall, providing effective relief within just two minutes of application. Packed in a convenient 25 ml High-Density Polyethylene (HDPE) bottle equipped with a metered dose valve pump, a single spray delivers 250 micrograms of Benzydamine Hydrochloride.

ICPA has expanded its product range with the introduction of Coolora spray, alongside the existing Coolora gargle. A spray form of delivery brings unique benefits, especially in easing post-tonsillectomy surgical pain for patients who struggle with gargling after the surgery.

Additionally, for children who have difficulty gargling, the spray would be more suitable because it eliminates the chances of gargle swallowing. This move reflects ICPA’s commitment to making healthcare more accessible for everyone.

The active ingredient in Coolora Spray, Benzydamine Hydrochloride 0.15 per cent, belongs to the category of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Operating in the throat and mouth, the spray effectively alleviates pain and inflammation by inhibiting the synthesis of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β).